Amar Deshpande, MD
Gastroenterology · Miami, FLNPI 1710189915
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,300 of the $3,341 with a category attached, or 98.8%. Pfizer accounts for 98.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for gastroenterology clinicians in FL, where the typical reported total is $3,025.
Across 2 payments — averaging $1670.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- AbbVie$41
Across 44 payments — averaging $5491.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$102K
- Takeda$98K
- Boehringer Ingelheim International GmbH$40K
- Sanofi US Services Inc.$2K
What the payments were for
- Speaking & faculty fees$3,30099%
- Food & beverage$411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$3,300
How this compares
$3,341 in reported general payments places this provider in the 50th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 11 | $509,364 |
| Mesalamine | 24 | $3,451 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Miami
- Lukasz KwapiszMiami$1.2M
- Joanna LopezMiami$670K
- Jerry MartelMiami$511K
- Andres GelrudMiami$208K
- Maria HernandezMiami$197K
- George SanchezMiami$117K
- Jodie BarkinMiami$101K
- Javier ParraMiami$68K
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.